4 recruiting, 1 active not recruiting, 1 completed. 6 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 4, Active not recruiting 1, Completed 1 |
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow CatalYm GmbH: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Visugromab in Cachexia International Trial Visugromab (CTL-002), Placebo - Cancer-associated Cachexia | Phase 2 / Phase 3 | Recruiting | CatalYm GmbH | 518 | 2026-04-16 | 2026-11-02 |
| Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure Visugromab RDE (recommended dose for expansion), Nivolumab, Lenvatinib - Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma | Phase 2 | Recruiting | CatalYm GmbH | 104 | 2026-03-19 | 2026-09-23 |
| Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab - Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor | Phase 2 | Recruiting | CatalYm GmbH | 131 | 2025-10-07 | 2026-10-26 |
| Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC Visugromab, Matching placebo for visugromab, Pembrolizumab 200 mg Q3W - Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor | Phase 2 | Recruiting | CatalYm GmbH | 107 | 2025-08-01 | 2026-10-19 |
| Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer Nivolumab, Visugromab (CTL-002), Placebo - Bladder Cancer, Adult Solid Tumor | Phase 2 | Completed | CatalYm GmbH | 31 | 2023-09-06 | 2026-08-19 |
| First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER) visugromab (CTL-002), nivolumab - Solid Tumor, Adult | Phase 1 / Phase 2 | Active not recruiting | CatalYm GmbH | 199 | 2020-12-09 | 2026-08-19 |
Anorexia (1) · Cachexia (1) · Carcinoma, Hepatocellular (1) · Neoplasms (1) · Urinary Bladder Neoplasms (1) · Weight Loss (1)
Nivolumab (4) · Saline Solution (2) · Docetaxel (1) · Pemetrexed (1) · lenvatinib (1) · pembrolizumab (1)
Germany (5) · Italy (5) · Spain (5) · Switzerland (4) · United States (4) · Poland (3) · Romania (3) · France (2) · United Kingdom (2) · Bulgaria (1) · Czechia (1) · Ireland (1) · Netherlands (1) · Norway (1)
Felix Lichtenegger, MD (2) · Frank Hermann, MD (1) · Lena Lemke, MD (1)
2025 (1)